TAFLOTAN

This brand name is authorized in Estonia, Finland, Germany, Hong Kong SAR China, Lithuania, Poland, Singapore.

Active ingredients

The drug TAFLOTAN contains one active pharmaceutical ingredient (API):

1	Tafluprost UNII 1O6WQ6T7G3 - TAFLUPROST
	Tafluprost is a fluorinated analogue of prostaglandin F2α. Tafluprost acid, the biologically active metabolite of tafluprost, is a highly potent and selective agonist of the human prostanoid FP receptor.
	Read more about Tafluprost

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01EE05	Tafluprost	S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	06707048, 06707054, 06707060, 09606945, 09606951, 10169332, 10169349, 10177739, 10177745, 10199209, 10199215, 11156828, 11156834, 11174306, 12641081, 12641098, 13703051, 13703068, 15317702, 15530324, 17633519
EE	Ravimiamet	1379303, 1379314, 1753703, 1753714, 1870040, 1870051
FI	Lääkealan turvallisuus- ja kehittämiskeskus	134352, 134374, 152938, 199670
HK	Department of Health Drug Office	59089, 63713
LT	Valstybinė vaistų kontrolės tarnyba	1034197, 1038195, 1086684, 1086685, 1093207
PL	Rejestru Produktów Leczniczych	100170325, 100395515
SG	Health Sciences Authority	13872P, 14856P